苯达莫司汀治疗的惰性非霍奇金淋巴瘤患者感染风险与抗菌预防:澳大利亚淋巴瘤联盟研究
这项多中心回顾性研究分析了302例接受苯达莫司汀治疗的惰性非霍奇金淋巴瘤患者的感染特征和抗菌预防。淋巴细胞减少几乎普遍存在且恢复时间与累积剂量相关,但淋巴细胞减少严重程度与感染无关。感染发生率为44%,与obinutuzumab和/或维持抗CD20治疗、既往治疗及晚期分期相关。
要点
- 淋巴细胞减少(<1×10^9/L)几乎普遍存在,恢复时间与累积苯达莫司汀剂量相关。
- 感染发生率为44%,其中32%发生在苯达莫司汀完成后≥3个月。
- VZV/HSV预防与较少感染相关(HR 0.14,p=0.061),PJP预防与细菌感染风险降低相关(HR 0.48,p=0.004)。
核心结论
- 研究表明无论淋巴细胞减少严重程度如何,感染风险均显著,支持通过预防措施降低早期和延迟感染风险。
研究设计与样本
- 多中心回顾性研究,纳入302例接受苯达莫司汀治疗的惰性非霍奇金淋巴瘤患者,分析感染特征和抗菌预防。
主要发现
- 淋巴细胞减少(<1×10^9/L)几乎普遍存在,淋巴细胞恢复时间与累积苯达莫司汀剂量相关。
- 未观察到淋巴细胞减少严重程度和持续时间与感染之间的关联。
- 感染发生在44%的患者中(50%为细菌性),27%需住院,32%的感染发生在苯达莫司汀完成后≥3个月。
- 感染与obinutuzumab和/或维持抗CD20治疗、既往治疗及晚期分期相关。
- 21例患者发生24次机会性感染:10例水痘-带状疱疹病毒(VZV),7例单纯疱疹病毒(HSV),1例巨细胞病毒,1例进行性多灶性白质脑病,1例诺卡菌病,1例耶氏肺孢子菌肺炎(PJP),3例其他真菌感染。
关键数值与推荐
- VZV/HSV预防和PJP预防分别被处方给42%和54%的患者。
- 接受预防的患者中VZV/HSV感染较少(HR 0.14,p=0.061)。
- PJP预防与细菌感染风险降低相关(HR 0.48,p=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infection and lymphopenia are established bendamustine-related complications. The relationship between lymphopenia severity and infection risk, and the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed infection characteristics and antimicrobial prophylaxis in 302 bendamustine-treated indolent non-Hodgkin lymphoma patients. Lymphopenia (<1 × 109/L) was near universal and time to lymphocyte recovery correlated with cumulative bendamustine dose. No association between lymphopenia severity and duration with infection was observed. Infections occurred in 44% of patients (50% bacterial) with 27% hospitalised; 32% of infections occurred ≥3 months post bendamustine completion. Infection was associated with obinutuzumab and/or maintenance anti-CD20 therapy, prior therapy and advanced stage. Twenty-four opportunistic infections occurred in 21 patients: ten varicella zoster virus (VZV), seven herpes simplex virus (HSV), one cytomegalovirus, one progressive multifocal leucoencephalopathy, one nocardiosis, one Pneumocystis jiroveci pneumonia (PJP) and three other fungal infections. VZV/HSV and PJP prophylaxis were prescribed to 42% and 54% respectively. Fewer VZV/HSV infections occurred in patients receiving prophylaxis (HR 0.14, p = 0.061) while PJP prophylaxis was associated with reduced risk of bacterial infection (HR 0.48, p = 0.004). Our study demonstrates a significant infection risk regardless of lymphopenia severity and supports prophylaxis to mitigate the risk of early and delayed infections.
引用
- Manos K, Churilov L, Grigg A, et al. Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study. Br J Haematol. 2024. PMID: 38485116. doi:10.1111/bjh.19407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。